Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients

R. Fazio, M. L. Malosio, V. Lampasona, D. De Feo, D. Privitera, F. Marnetto, D. Centonze, A. Ghezzi, G. Comi, R. Furlan, G. Martino

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background: Antibodies against aquaporin-4 (AQP4), a water channel particularly expressed on perivascular astrocytic podocytes, are proposed as a marker for the diagnosis of neuromyelitis optica (NMO). However, a consensus on seroprevalence and optimal detection method has not yet been reached. Objectives: To investigate the performance of different assays to detect anti-AQP4 antibodies. Methods: We set up five different assays. Two of them were capable to detect perivascular lgG reactivity on brain tissue by immunofluorescence (NMO-lgG). Other three assays have been set to detect anti-AQP4 antibodies: immunofluorescence and flow cytometry on AQP4-expressing cells, and a radioimmunoprecipitation assay. We assessed sensitivity and specificity of these assays by interrogating sera of 33 NMO patients, 13 patients at high risk to develop NMO (hrNMO), 6 patients affected by acute partial transverse myelitis (APTM), 20 patients with multiple sclerosis (MS), and 67 age- and sex-matched healthy controls. Results: We found that the presence of serum NMO-lgG and anti-AQP4 reactivity is almost exclusively restricted to patients with NMO and hrNMO. Seroprevalence and sensitivity ranged from 30 to 47%, depending on the assay. Specificity ranged from 95 to 100%. Comparing results obtained in the five assays, we noticed lack of concordance in some samples. Conclusions: Detection of NMO-lgG or anti-AQP4 antibodies may represent a valuable tool to assist neurologists in the differential diagnosis between patients with NMO, hrNMO, APTM, or MS. The current lack of a gold standard to detect anti-AQP4 antibodies implies the necessity to standardize the detection of these antibodies.

Original languageEnglish
Pages (from-to)1153-1163
Number of pages11
JournalMultiple Sclerosis Journal
Volume15
Issue number10
DOIs
Publication statusPublished - 2009

Fingerprint

Neuromyelitis Optica
Aquaporin 4
Antibodies
Transverse Myelitis
Seroepidemiologic Studies
Multiple Sclerosis
Fluorescent Antibody Technique
Radioimmunoprecipitation Assay
Podocytes
Aquaporins
Serum
Flow Cytometry
Differential Diagnosis
Sensitivity and Specificity

Keywords

  • Neuromyelitis optica

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. / Fazio, R.; Malosio, M. L.; Lampasona, V.; De Feo, D.; Privitera, D.; Marnetto, F.; Centonze, D.; Ghezzi, A.; Comi, G.; Furlan, R.; Martino, G.

In: Multiple Sclerosis Journal, Vol. 15, No. 10, 2009, p. 1153-1163.

Research output: Contribution to journalArticle

@article{117016ada4184336a9f8b61432a8bc02,
title = "Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients",
abstract = "Background: Antibodies against aquaporin-4 (AQP4), a water channel particularly expressed on perivascular astrocytic podocytes, are proposed as a marker for the diagnosis of neuromyelitis optica (NMO). However, a consensus on seroprevalence and optimal detection method has not yet been reached. Objectives: To investigate the performance of different assays to detect anti-AQP4 antibodies. Methods: We set up five different assays. Two of them were capable to detect perivascular lgG reactivity on brain tissue by immunofluorescence (NMO-lgG). Other three assays have been set to detect anti-AQP4 antibodies: immunofluorescence and flow cytometry on AQP4-expressing cells, and a radioimmunoprecipitation assay. We assessed sensitivity and specificity of these assays by interrogating sera of 33 NMO patients, 13 patients at high risk to develop NMO (hrNMO), 6 patients affected by acute partial transverse myelitis (APTM), 20 patients with multiple sclerosis (MS), and 67 age- and sex-matched healthy controls. Results: We found that the presence of serum NMO-lgG and anti-AQP4 reactivity is almost exclusively restricted to patients with NMO and hrNMO. Seroprevalence and sensitivity ranged from 30 to 47{\%}, depending on the assay. Specificity ranged from 95 to 100{\%}. Comparing results obtained in the five assays, we noticed lack of concordance in some samples. Conclusions: Detection of NMO-lgG or anti-AQP4 antibodies may represent a valuable tool to assist neurologists in the differential diagnosis between patients with NMO, hrNMO, APTM, or MS. The current lack of a gold standard to detect anti-AQP4 antibodies implies the necessity to standardize the detection of these antibodies.",
keywords = "Neuromyelitis optica",
author = "R. Fazio and Malosio, {M. L.} and V. Lampasona and {De Feo}, D. and D. Privitera and F. Marnetto and D. Centonze and A. Ghezzi and G. Comi and R. Furlan and G. Martino",
year = "2009",
doi = "10.1177/1352458509106851",
language = "English",
volume = "15",
pages = "1153--1163",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "10",

}

TY - JOUR

T1 - Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients

AU - Fazio, R.

AU - Malosio, M. L.

AU - Lampasona, V.

AU - De Feo, D.

AU - Privitera, D.

AU - Marnetto, F.

AU - Centonze, D.

AU - Ghezzi, A.

AU - Comi, G.

AU - Furlan, R.

AU - Martino, G.

PY - 2009

Y1 - 2009

N2 - Background: Antibodies against aquaporin-4 (AQP4), a water channel particularly expressed on perivascular astrocytic podocytes, are proposed as a marker for the diagnosis of neuromyelitis optica (NMO). However, a consensus on seroprevalence and optimal detection method has not yet been reached. Objectives: To investigate the performance of different assays to detect anti-AQP4 antibodies. Methods: We set up five different assays. Two of them were capable to detect perivascular lgG reactivity on brain tissue by immunofluorescence (NMO-lgG). Other three assays have been set to detect anti-AQP4 antibodies: immunofluorescence and flow cytometry on AQP4-expressing cells, and a radioimmunoprecipitation assay. We assessed sensitivity and specificity of these assays by interrogating sera of 33 NMO patients, 13 patients at high risk to develop NMO (hrNMO), 6 patients affected by acute partial transverse myelitis (APTM), 20 patients with multiple sclerosis (MS), and 67 age- and sex-matched healthy controls. Results: We found that the presence of serum NMO-lgG and anti-AQP4 reactivity is almost exclusively restricted to patients with NMO and hrNMO. Seroprevalence and sensitivity ranged from 30 to 47%, depending on the assay. Specificity ranged from 95 to 100%. Comparing results obtained in the five assays, we noticed lack of concordance in some samples. Conclusions: Detection of NMO-lgG or anti-AQP4 antibodies may represent a valuable tool to assist neurologists in the differential diagnosis between patients with NMO, hrNMO, APTM, or MS. The current lack of a gold standard to detect anti-AQP4 antibodies implies the necessity to standardize the detection of these antibodies.

AB - Background: Antibodies against aquaporin-4 (AQP4), a water channel particularly expressed on perivascular astrocytic podocytes, are proposed as a marker for the diagnosis of neuromyelitis optica (NMO). However, a consensus on seroprevalence and optimal detection method has not yet been reached. Objectives: To investigate the performance of different assays to detect anti-AQP4 antibodies. Methods: We set up five different assays. Two of them were capable to detect perivascular lgG reactivity on brain tissue by immunofluorescence (NMO-lgG). Other three assays have been set to detect anti-AQP4 antibodies: immunofluorescence and flow cytometry on AQP4-expressing cells, and a radioimmunoprecipitation assay. We assessed sensitivity and specificity of these assays by interrogating sera of 33 NMO patients, 13 patients at high risk to develop NMO (hrNMO), 6 patients affected by acute partial transverse myelitis (APTM), 20 patients with multiple sclerosis (MS), and 67 age- and sex-matched healthy controls. Results: We found that the presence of serum NMO-lgG and anti-AQP4 reactivity is almost exclusively restricted to patients with NMO and hrNMO. Seroprevalence and sensitivity ranged from 30 to 47%, depending on the assay. Specificity ranged from 95 to 100%. Comparing results obtained in the five assays, we noticed lack of concordance in some samples. Conclusions: Detection of NMO-lgG or anti-AQP4 antibodies may represent a valuable tool to assist neurologists in the differential diagnosis between patients with NMO, hrNMO, APTM, or MS. The current lack of a gold standard to detect anti-AQP4 antibodies implies the necessity to standardize the detection of these antibodies.

KW - Neuromyelitis optica

UR - http://www.scopus.com/inward/record.url?scp=72449188825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449188825&partnerID=8YFLogxK

U2 - 10.1177/1352458509106851

DO - 10.1177/1352458509106851

M3 - Article

C2 - 19667009

AN - SCOPUS:72449188825

VL - 15

SP - 1153

EP - 1163

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 10

ER -